|
US6365787B1
(en)
|
1994-09-30 |
2002-04-02 |
The Johns Hopkins University |
Compounds for the suppression of HIV TAT transactivation
|
|
US6245523B1
(en)
*
|
1996-11-20 |
2001-06-12 |
Yale University |
Survivin, a protein that inhibits cellular apoptosis, and its modulation
|
|
US20030033621A1
(en)
*
|
1997-02-26 |
2003-02-13 |
De La Monte Suzanne |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
|
|
CA2282729A1
(en)
*
|
1997-02-26 |
1998-09-03 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
|
|
US7226730B1
(en)
*
|
1997-02-26 |
2007-06-05 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
|
|
EP1066527A2
(en)
*
|
1998-04-01 |
2001-01-10 |
Yale University |
Method to identify modulators of survivin - tubulin interaction
|
|
WO2000003693A1
(en)
*
|
1998-07-14 |
2000-01-27 |
Jenner Biotherapies, Inc. |
Survivin, and peptides thereof, as an anti-cancer vaccine
|
|
US6335194B1
(en)
*
|
1998-09-29 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
US6077709A
(en)
*
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6838283B2
(en)
|
1998-09-29 |
2005-01-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of survivin expression
|
|
AU2003205017B2
(en)
*
|
1998-09-29 |
2005-12-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
|
US6608108B2
(en)
*
|
1999-10-15 |
2003-08-19 |
Johns Hopkins University |
Method for treatment of tumors using nordihydroguaiaretic acid derivatives
|
|
AU784634B2
(en)
|
1999-11-30 |
2006-05-18 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
EP1237582B1
(en)
|
1999-12-10 |
2011-09-14 |
AntiCancer, Inc. |
Methods for introducing genes into mammalian subjects
|
|
US6509162B1
(en)
|
2000-02-29 |
2003-01-21 |
Yale University |
Methods for selectively modulating survivin apoptosis pathways
|
|
AU2001273102A1
(en)
*
|
2000-06-29 |
2002-01-14 |
The Salk Institute For Biological Studies |
Crystal structure of survivin
|
|
US7776518B2
(en)
|
2001-01-12 |
2010-08-17 |
Yale University |
Detection of survivin in the biological fluids of cancer patients
|
|
US7097966B2
(en)
|
2001-01-12 |
2006-08-29 |
Yale University |
Detection of survivin in the biological fluids of cancer patients
|
|
DE10102722A1
(de)
*
|
2001-01-22 |
2002-08-14 |
Medinnova Ges Med Innovationen |
Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen
|
|
WO2003061519A2
(en)
*
|
2002-01-18 |
2003-07-31 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US7892559B2
(en)
|
2002-01-30 |
2011-02-22 |
Survac Aps |
Survivin-derived peptides and use thereof
|
|
US20040210035A1
(en)
*
|
2002-01-30 |
2004-10-21 |
Straten Eivind Per Thor |
Survivin-derived peptides and use thereof
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040102395A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of IAP-like expression
|
|
AU2003295598B2
(en)
|
2002-11-15 |
2009-12-24 |
Genomic Health, Inc. |
Gene expression profiling of EGFR positive cancer
|
|
WO2004058293A1
(en)
*
|
2002-12-24 |
2004-07-15 |
Northern Therapeutics Inc. |
Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension
|
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
|
ES2633389T3
(es)
|
2003-01-30 |
2017-09-21 |
Survac Aps |
Péptidos derivados de survivina y uso de los mismos
|
|
CA2515096A1
(en)
*
|
2003-02-06 |
2004-08-26 |
Genomic Health, Inc. |
Gene expression markers for response to egfr inhibitor drugs
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
CA2516553C
(en)
*
|
2003-02-20 |
2013-04-16 |
Genomic Health, Inc. |
Use of intronic rna to measure gene expression
|
|
DE602004027902D1
(de)
*
|
2003-03-24 |
2010-08-12 |
Scripps Research Inst |
Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
|
|
EP1636380A2
(en)
*
|
2003-05-30 |
2006-03-22 |
Genomic Health, Inc. |
Gene expression markers for response to egfr inhibitor drugs
|
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
|
ES2609234T3
(es)
|
2003-06-24 |
2017-04-19 |
Genomic Health, Inc. |
Predicción de la probabilidad de recidiva de cáncer
|
|
US7526387B2
(en)
|
2003-07-10 |
2009-04-28 |
Genomic Health, Inc. |
Expression profile algorithm and test for cancer prognosis
|
|
CA2542656A1
(en)
*
|
2003-10-16 |
2005-05-06 |
Genomic Health, Inc. |
Qrt-pcr assay system for gene expression profiling
|
|
WO2005049073A2
(en)
|
2003-11-19 |
2005-06-02 |
Survac Aps |
Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
|
|
CA2551267C
(en)
*
|
2003-12-23 |
2012-05-01 |
Genomic Health, Inc. |
Universal amplification of fragmented rna
|
|
CA2563074C
(en)
|
2004-04-09 |
2014-05-20 |
Genomic Health, Inc. |
Gene expression markers for predicting response to chemotherapy
|
|
EP1756308A1
(en)
*
|
2004-04-23 |
2007-02-28 |
Exagen Diagnostics, Inc. |
Compositions and methods for breast cancer prognosis
|
|
US7342093B2
(en)
*
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
|
ES2671893T3
(es)
|
2004-10-06 |
2018-06-11 |
Mayo Foundation For Medical Education And Research |
B7-H1 y PD-1 en el tratamiento del carcinoma de células renales
|
|
JP5020088B2
(ja)
*
|
2004-11-05 |
2012-09-05 |
ジェノミック ヘルス， インコーポレイテッド |
遺伝子発現マーカーを使用する、化学療法に対する反応の予測
|
|
EP1815014B1
(en)
*
|
2004-11-05 |
2012-03-21 |
Genomic Health, Inc. |
Molecular indicators of breast cancer prognosis and prediction of treatment response
|
|
KR20070095882A
(ko)
|
2004-11-09 |
2007-10-01 |
산타리스 팔마 에이/에스 |
Ｌｎａ 올리고뉴클레오티드 및 암의 치료
|
|
WO2006051075A1
(en)
|
2004-11-12 |
2006-05-18 |
Vib Vzw |
Use of survivin to treat kidney failure
|
|
US20060135461A1
(en)
*
|
2004-12-22 |
2006-06-22 |
Natalia Botchkareva |
Reduction of hair growth
|
|
CN103143004A
(zh)
|
2005-02-04 |
2013-06-12 |
萨瓦克公司 |
存活蛋白肽疫苗
|
|
US7803375B2
(en)
*
|
2005-02-23 |
2010-09-28 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
|
US20060276423A1
(en)
*
|
2005-04-18 |
2006-12-07 |
Rachel Altura |
Survivin-directed RNA interference-compositions and methods
|
|
WO2006125117A2
(en)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
US7272013B1
(en)
*
|
2005-07-28 |
2007-09-18 |
American Megatrends, Inc. |
Interchangeable design support system
|
|
WO2007019427A2
(en)
*
|
2005-08-08 |
2007-02-15 |
Massachusetts Eye & Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US7812173B2
(en)
*
|
2005-08-23 |
2010-10-12 |
E.I. Du Pont De Nemours And Company |
Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications
|
|
US20070049752A1
(en)
*
|
2005-08-23 |
2007-03-01 |
Drysdale Neville E |
Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
AU2007353412A1
(en)
*
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
|
US8974526B2
(en)
*
|
2007-08-27 |
2015-03-10 |
Amo Groningen B.V. |
Multizonal lens with extended depth of focus
|
|
US9216080B2
(en)
|
2007-08-27 |
2015-12-22 |
Amo Groningen B.V. |
Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same
|
|
US8466140B2
(en)
*
|
2007-09-10 |
2013-06-18 |
University Of Massachusetts |
Mitochondria-targeted anti-tumor agents
|
|
ATE523810T1
(de)
|
2008-02-15 |
2011-09-15 |
Amo Regional Holdings |
System, brillenglas und verfahren zur erweiterung der fokustiefe
|
|
US8439498B2
(en)
|
2008-02-21 |
2013-05-14 |
Abbott Medical Optics Inc. |
Toric intraocular lens with modified power characteristics
|
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
|
AU2009228146B2
(en)
|
2008-03-28 |
2015-06-04 |
Johnson & Johnson Surgical Vision, Inc. |
Systems for ocular measurements
|
|
CN101981187A
(zh)
*
|
2008-03-31 |
2011-02-23 |
株式会社生物免疫平衡 |
MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法
|
|
US8862447B2
(en)
|
2010-04-30 |
2014-10-14 |
Amo Groningen B.V. |
Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses
|
|
EP3824846B1
(en)
|
2009-12-18 |
2024-10-30 |
AMO Groningen B.V. |
Limited echelette lens
|
|
US20130137642A1
(en)
|
2010-04-23 |
2013-05-30 |
Demetrios Vavvas |
Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
|
|
US20140024598A1
(en)
|
2010-11-01 |
2014-01-23 |
Demetrios Vavvas |
Methods and compositions for preserving retinal ganglion cells
|
|
US9817246B2
(en)
|
2010-12-01 |
2017-11-14 |
Amo Groningen B.V. |
Multifocal lens having an optical add power progression, and a system and method of providing same
|
|
EP2773341A2
(en)
|
2011-10-21 |
2014-09-10 |
Massachusetts Eye & Ear Infirmary |
Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
|
|
US9717628B2
(en)
|
2012-12-04 |
2017-08-01 |
Amo Groningen B.V. |
Lenses, systems and methods for providing binocular customized treatments to correct presbyopia
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US10022441B2
(en)
|
2013-03-27 |
2018-07-17 |
Immunovaccine Technologies, Inc. |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
US20160279213A1
(en)
*
|
2013-12-16 |
2016-09-29 |
Merck Patent Gmbh |
Survivin-Directed Cancer Vaccine Therapy
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
JP2018509384A
(ja)
|
2015-01-06 |
2018-04-05 |
イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． |
リピドａ模倣体、調製方法、及びその使用
|
|
WO2016179573A1
(en)
*
|
2015-05-07 |
2016-11-10 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Variant survivin vaccine for treatment of cancer
|
|
ES2883128T3
(es)
|
2015-09-04 |
2021-12-07 |
Health Research Inc |
Anticuerpos anti-survivina para la terapia contra el cáncer
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
EP3377099A4
(en)
|
2015-11-18 |
2019-07-24 |
ImmunoVaccine Technologies Inc. |
ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
|
|
CA3013858A1
(en)
|
2016-02-09 |
2017-08-17 |
Amo Groningen B.V. |
Progressive power intraocular lens, and methods of use and manufacture
|
|
AU2017237076B2
(en)
|
2016-03-23 |
2021-11-18 |
Johnson & Johnson Surgical Vision, Inc. |
Ophthalmic apparatus with corrective meridians having extended tolerance band with freeform refractive surfaces
|
|
EP3932368B1
(en)
|
2016-03-23 |
2025-02-26 |
Johnson & Johnson Surgical Vision, Inc. |
Ophthalmic apparatus with corrective meridians having extended tolerance band
|
|
US11060087B2
(en)
*
|
2016-06-15 |
2021-07-13 |
The Regents Of The University Of California |
Synthetic promoters for high throughput screening and gene modulation
|
|
EP3522771B1
(en)
|
2016-10-25 |
2022-04-06 |
Amo Groningen B.V. |
Realistic eye models to design and evaluate intraocular lenses for a large field of view
|
|
US10739227B2
(en)
|
2017-03-23 |
2020-08-11 |
Johnson & Johnson Surgical Vision, Inc. |
Methods and systems for measuring image quality
|
|
AU2018376564B2
(en)
|
2017-11-30 |
2024-11-14 |
Amo Groningen B.V. |
Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof
|
|
FR3087448B1
(fr)
|
2018-10-23 |
2023-10-13 |
Pdc Line Pharma |
Lignee pdc modifiee pour secreter une cytokine
|
|
US12264189B2
(en)
|
2018-10-31 |
2025-04-01 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
WO2020092736A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US11886046B2
(en)
|
2019-12-30 |
2024-01-30 |
Amo Groningen B.V. |
Multi-region refractive lenses for vision treatment
|
|
WO2022233683A1
(en)
|
2021-05-05 |
2022-11-10 |
Amo Groningen B.V. |
Ring halometer system and method for quantifying dysphotopsias
|
|
AU2022403148A1
(en)
|
2021-12-03 |
2024-07-18 |
Amo Groningen B.V. |
Lenses having multi-ring design for vision treatment
|